



Published in final edited form as:

*Nat Immunol.* 2015 February ; 16(2): 142–152. doi:10.1038/ni.3054.

## Pathophysiology of T follicular helper cells in humans and mice

Hideki Ueno<sup>1</sup>, Jacques Banchereau<sup>2</sup>, and Carola G Vinuesa<sup>3</sup>

<sup>1</sup>Baylor Institute for Immunology Research, Dallas, Texas, USA

<sup>2</sup>Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, USA, and Vaccine Research Institute, INSERM U955, Hopital Henri Mondor, Creteil, France

<sup>3</sup>Department of Pathogens and Immunity, John Curtin School of Medical Research, Australian National University, Canberra, Australia

### Abstract

Follicular helper T cells (T<sub>FH</sub> cells) compose a heterogeneous subset of CD4<sup>+</sup> T cells that induce the differentiation of B cells into plasma cells and memory cells. They are found within and in proximity to germinal centers in secondary lymphoid organs, and their memory compartment also circulates in the blood. Our knowledge on the biology of T<sub>FH</sub> cells has increased significantly during the past decade, largely as a result of mouse studies. However, recent studies on human T<sub>FH</sub> cells isolated from lymphoid organ and blood samples and recent observations on the developmental mechanism of human T<sub>FH</sub> cells have revealed both similarities and differences between human and mouse T<sub>FH</sub> cells. Here we present the similarities and differences between mouse and human lymphoid organ–resident T<sub>FH</sub> cells and discuss the role of T<sub>FH</sub> cells in response to vaccines and in disease pathogenesis.

---

A number of seminal discoveries made in mice and humans led to the description of B follicular helper T (T<sub>FH</sub>) cells in the early 2000s. The requirement of T cell help for the development of antibody responses was first described in the 1960s (ref. 1). CD4<sup>+</sup> helper T cells (T<sub>H</sub> cells) were then found to be necessary for the development of germinal centers, discrete structures in secondary lymphoid organs where the selection of high-affinity B cells and the development of B cell memory occur<sup>2–4</sup>. *In vitro* studies in the 1980s, mostly involving CD4<sup>+</sup> T cell clones and recombinant cytokines, showed that T<sub>H2</sub> cells are the major T<sub>H</sub> subset engaged in helping B cells by secreting interleukin 4 (IL-4) and IL-10 (refs. 5,6). In mouse, T<sub>H1</sub> cells also contribute to the regulation of antibody responses by inducing B cell class switching toward IgG2a. However, for almost two decades it was unclear how the T<sub>H1</sub> and T<sub>H2</sub> cells engaged in B cell help in lymphoid organs were biologically and developmentally distinct from those that exit lymphoid organs and migrate into peripheral tissues. The chemokine receptor CXCR5 was discovered in 1993 as a G protein–coupled

---

© 2015 Nature America, Inc. All rights reserved.

Reprints and permissions information is available online at <http://www.nature.com/reprints/index.html>.

Correspondence should be addressed to H.U. (hidekiu@baylorhealth.edu), J.B. (Jacques.banchereau@Jax.org) and C.G.V. (carola.vinuesa@anu.edu.au).

### COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

receptor expressed primarily by B cells<sup>7</sup>, and in 1996 it was shown to be critical for the migration of B cells into follicles in lymphoid organs in mice<sup>8</sup>. In 1999, CD4<sup>+</sup> T cells activated in lymphoid organs of immunized mice were found to express CXCR5, which was required for the cells' migration into follicles<sup>9</sup>. In the early 2000s, studies on CD4<sup>+</sup> T cells in human tonsils showed that cells expressing CXCR5 have a superior capacity to induce immunoglobulin production in B cells *in vitro* relative to CD4<sup>+</sup> T cells lacking CXCR5 expression. On the basis of their localization and functions, tonsillar CXCR5<sup>+</sup> CD4<sup>+</sup> T cells were designated as T<sub>FH</sub> cells<sup>10–12</sup>. A similar CD4<sup>+</sup> T cell subset was found in mouse lymph nodes<sup>13</sup>. Profiling of cytokine production and gene expression in human and mouse T<sub>FH</sub> cells showed that these cells are distinct from T<sub>H</sub>1 and T<sub>H</sub>2 cells<sup>14–16</sup> and help B cells mainly by delivering activating signals with the TNF family molecule CD40L and the cytokine IL-21 (refs. 14,17–20). In 2009, the transcription repressor Bcl-6 was discovered to be an essential factor for T<sub>FH</sub> cell generation *in vivo* in mice<sup>21–23</sup>, and since then T<sub>FH</sub> cells have been recognized as an independent T<sub>H</sub> subset distinct from T<sub>H</sub>1, T<sub>H</sub>2 and T<sub>H</sub>17 cells.

Our knowledge of the biology of T<sub>FH</sub> cells has increased significantly during the past decade (reviewed in refs. 24,25). Like in other fields of immunology, important biological features of T<sub>FH</sub> cells have been learned of from studies in mouse models, whereas studies of the ontogeny and function of T<sub>FH</sub> cells in humans have remained relatively limited, mainly because of difficulties in investigating and manipulating T<sub>FH</sub> cells from human secondary lymphoid organs. Furthermore, there are only two main sources of human T<sub>FH</sub> cells for research: tonsils from children who have experienced recurrent throat infections but are otherwise healthy, and spleens, generally from cadaveric organ donors. This poses a challenge in investigations of human T<sub>FH</sub> cells' association with human diseases such as cancer and autoimmunity. Over 60 million years of independent evolution have introduced significant differences in the immune systems of humans and mice. Thus, it is important to address whether conclusions drawn in mouse T<sub>FH</sub> studies also hold true for human T<sub>FH</sub> cells. Recent progress in our understanding of the biology of blood-circulating T<sub>FH</sub> cells in humans has provided clues on how to determine whether alteration of T<sub>FH</sub> responses contributes to human diseases. Furthermore, analyses of blood memory T<sub>FH</sub> cells (and also lymph node cells in some instances) from patients with primary or acquired immunodeficiencies have also provided important insights regarding the development and/or maintenance of T<sub>FH</sub> cells in humans. Together with *in vitro* studies aiming at determining the developmental mechanisms of human T<sub>FH</sub> cells, these studies have started revealing similarities as well as differences between humans and mice.

In this review, we first summarize our current knowledge of the biology of lymphoid organ T<sub>FH</sub> cells and discuss the similarities and differences between these cells in mice and humans. Then we discuss recent findings on the circulating memory compartment of T<sub>FH</sub> cells in human blood (hereinafter called blood memory T<sub>FH</sub> cells). Last, we summarize recent insights into the role of T<sub>FH</sub> cells in disease pathogenesis and discuss how T<sub>FH</sub> cells participate in or contribute to both beneficial and aberrant immune responses observed in various human diseases.

## T<sub>FH</sub> subsets and dynamics in mice

Recent studies in mice and humans show that T<sub>FH</sub> lineage cells in lymphoid organs are composed of subsets that differ in their localization, phenotype and function. The circulating memory compartment of T<sub>FH</sub> cells in human blood also contains subsets that differ in phenotype and function.

Studies in mice have shown that after interaction with dendritic cells (DCs) in the T cell zones of secondary lymphoid organs, a fraction of activated CD4<sup>+</sup> T cells migrate toward B cell follicles by upregulating the chemokine receptor CXCR5 (refs. 9,26) (mediated by increased expression of the transcription factors Bcl-6 (refs. 27,28) and Acl2 (ref. 29)) while downregulating the chemokine receptor CCR7 (ref. 30) and the cell adhesion molecule PSGL-1 (ref. 31). These CXCR5<sup>+</sup>Bcl-6<sup>+</sup>CD4<sup>+</sup> T cells (hereinafter called T<sub>FH</sub> precursors) interact with antigen-presenting B cells at the border of the B cell follicle and T cell zone<sup>9,32</sup>, a required process for the generation of germinal center (GC)-resident T<sub>FH</sub> cells (GC T<sub>FH</sub> cells) and the differentiation of primed B cells along both GC and extrafollicular pathways<sup>33</sup>. Bcl-6 expression in CD4<sup>+</sup> T cells is a prerequisite for GC formation<sup>21–23</sup>. The origin of T<sub>FH</sub> cells is not restricted to naive cells, and there is some evidence suggesting that other T<sub>H</sub> subsets including T<sub>H</sub>1, T<sub>H</sub>2, T<sub>H</sub>17 and regulatory T (T<sub>reg</sub>) cells may become T<sub>FH</sub> cells in GCs (reviewed in ref. 25). This is consistent with the heterogeneity in cytokine expression patterns among GC T<sub>FH</sub> cells developed under different immunization protocols and by different types of infectious agents (reviewed in ref. 34).

In mice, GC T<sub>FH</sub> cells and T<sub>FH</sub> precursors have been defined largely on the basis of differences in cell surface markers, particularly the expression of CXCR5 and PD-1, which are more highly expressed in GC T<sub>FH</sub> cells than in their precursors outside GCs. During the acute or early phase following immunization, IL-21 is expressed almost exclusively by CXCR5<sup>hi</sup>PD-1<sup>hi</sup> GC T<sub>FH</sub> cells in lymphoid organs<sup>35</sup>. Investigation of T<sub>FH</sub> cells is, however, no longer restricted to their identification on the basis of phenotypic markers and cytokine secretion; it is now possible to visualize and track GC T<sub>FH</sub> cells directly with intravital imaging. Such imaging studies have revealed that GC T<sub>FH</sub> cells display unique cell dynamics: GC T<sub>FH</sub> cells continuously immigrate and redistribute to other follicles and neighboring GCs<sup>36</sup>, in a manner dependent on high expression of CXCR5 and the trafficking molecule sphingosine-1-phosphate receptor 2 (S1PR2)<sup>37</sup>. Signals derived from interacting B cells induce GC T<sub>FH</sub> cells to increase intracellular Ca<sup>2+</sup> and their expression of IL-4 and IL-21, which enhance their capacity to promote the growth and differentiation of B cells<sup>38</sup>. A dynamic exchange of GC T<sub>FH</sub> cells among multiple GCs and bidirectional signals between GC T<sub>FH</sub> cells and B cells during their cognate interactions likely represent important mechanisms associated with the efficient selection and expansion of high-affinity B cells during GC responses. GC T<sub>FH</sub> cells exiting GCs rarely remain in the T cell zone or enter the bloodstream (at least while GC responses are actively in progress)<sup>36</sup>, suggesting that GC T<sub>FH</sub> cells and their precursors display different cell dynamics.

Mouse studies also identified cell subsets important for the suppression of GC response<sup>34</sup>. These suppressors contain Foxp3<sup>+</sup> T follicular regulatory (T<sub>FR</sub>) cells<sup>39–41</sup>. Current evidence

shows that, at least in mice,  $T_{FR}$  cells are differentiated from thymus-derived  $Foxp3^+$  regulatory T cells.  $T_{FR}$  cells dampen GC responses by limiting the numbers of both  $T_{FH}$  and B cells in GCs<sup>39–41</sup>. Given that mice lacking functional  $T_{FR}$  cells favor the accumulation of non-antigen-specific B cells<sup>40</sup>,  $T_{FR}$  cells might be specialized in repressing self-reactive B cells in GCs.  $T_{FR}$  cells are also likely to be responsible for terminating the GC response<sup>39</sup>. In either case, the balance between  $T_{FH}$  and  $T_{FR}$  cells in the GC environment likely represents a key factor in the generation of both high-affinity protective antibodies and pathogenic autoantibodies.

## $T_{FH}$ subsets in human tonsils

Studies in the early 1980s showed that  $CD4^+$  T cells in human tonsillar GCs express CD57 (ref. 42) and that these  $CD57^+$  T cells display a limited ability to express IL-2 (ref. 43). Although early studies suggested that CD57 is a marker for functionally mature GC  $T_{FH}$  cells in humans, CD57 is expressed by only approximately 30% of GC  $T_{FH}$  cells, and it is also expressed by a fraction (~10%) of  $CD4^+$  T cells localized outside GCs<sup>15,18</sup>.  $T_{FH}$  cells in human GCs are currently defined by their high expression of CXCR5, inducible costimulator (ICOS) and T cell inhibitory receptor PD-1 (refs. 15,18,44). Of note, ICOS is not a useful marker for defining GC  $T_{FH}$  cells in mice, as ICOS expression is largely similar between GC  $T_{FH}$  cells and  $T_{FH}$  precursors<sup>36</sup>. In human tonsils,  $Foxp3^+$   $T_{FR}$  cells within GCs are much rarer than in mice (unpublished observations), and current knowledge on human  $T_{FR}$  cells is very limited.

While Bcl-6 is well recognized as a transcription factor defining the  $T_{FH}$  lineage, mouse studies show that GC  $T_{FH}$  cells contain cells coexpressing Bcl-6 and T-bet (the transcription factor typically expressed by  $T_{H1}$  cells)<sup>35,45</sup>. In humans, GC  $T_{FH}$  cells in tonsils also contain a subset coexpressing Bcl-6 and ROR $\gamma$ t (the transcription factor typically expressed by  $T_{H17}$  cells), in addition to a subset coexpressing Bcl-6 and T-bet<sup>46</sup>. It remains to be established whether these GC  $T_{FH}$  cell subsets and GC  $T_{FH}$  cells lacking expression of T-bet or ROR $\gamma$ t have distinct functions; nevertheless, this observation suggests that other  $T_H$  subsets might be able to differentiate into  $T_{FH}$  cells in humans, similar to cells in mice. An alternative explanation is that there are developmental paths that are shared between  $T_{H1}$  and  $T_{FH}$  cells and between  $T_{H17}$  and  $T_{FH}$  cells in humans, as also proposed in mice<sup>47,48</sup>.

Recent data point to the possibility that the development of  $T_{FH}$  cells might differ between mice and humans. In humans, the cytokine TGF- $\beta$  acts with IL-12 and IL-23 to promote the expression of multiple  $T_{FH}$  molecules, including CXCR5, IL-21 and Bcl-6 (ref. 46), on activated naive  $CD4^+$  T cells (Fig. 1). Furthermore, human  $CD4^+$  T cells cultured under conditions used to generate  $T_{H17}$  cells (for example, a combination of TGF- $\beta$ , IL-23, IL-6 and IL-1 $\beta$ ) coexpress  $T_{FH}$  molecules and  $T_{H17}$  molecules<sup>46</sup>. This is in stark contrast to mouse  $CD4^+$  T cells, in which TGF- $\beta$  signals suppress the expression of  $T_{FH}$  molecules including IL-21, ICOS and Bcl-6 (refs. 21,46,49,50).

In human tonsils,  $CD4^+$  T cells expressing low amounts of CXCR5 and ICOS ( $CXCR5^{lo}ICOS^{lo}$  cells) are exclusively localized outside GCs<sup>18</sup>.  $CXCR5^{lo}ICOS^{lo}CD4^+$  T cells in tonsils appear to be  $T_{FH}$  precursors (or extrafollicular helper T cells), as these cells

express multiple  $T_{FH}$  molecules such as CD40L, IL-21 and CXCL13 but lack the expression of Bcl-6 protein<sup>18</sup>. Functionally, isolated CXCR5<sup>lo</sup>ICOS<sup>lo</sup>CD4<sup>+</sup> T cells are more effective than  $T_{FH}$  cells *in vitro* at helping naive B cells to become immunoglobulin-producing cells, possibly because they produce large amounts of IL-21. In contrast, GC  $T_{FH}$  cells but not CXCR5<sup>lo</sup>ICOS<sup>lo</sup>CD4<sup>+</sup> T cells provide help to GC B cells and promote their survival, proliferation and differentiation into immunoglobulin-producing cells *in vitro*. The inability of CXCR5<sup>lo</sup>ICOS<sup>lo</sup>CD4<sup>+</sup> T cells to help GC B cells is due to their expression of Fas ligand, which induces the death of Fas-expressing GC B cells<sup>18</sup>. Thus,  $T_{FH}$  cells at different maturation stages differ in their location and biological functions in human tonsils<sup>18</sup>. The observation that human  $T_{FH}$  precursors help naive B cells is consistent with the presence of mouse  $T_{FH}$  precursors with low expression of PD-1 and Bcl-6 at the T-B border shortly after T cell priming and before the induction of GCs<sup>33</sup>. These T cells likely induce the differentiation of B cells that have recently engaged their antigen receptors.

### Memory $T_{FH}$ subsets in human blood

CD4<sup>+</sup> T cells expressing the chemokine receptor CXCR5 were first described in human blood in 1994 (ref. 51) and were considered to represent recently activated T cells<sup>10,12,52</sup>. More recent studies indicate that blood CXCR5<sup>+</sup>CD4<sup>+</sup> T cells contain long-lived memory cells that share functional properties with  $T_{FH}$  cells<sup>53</sup>. Accordingly, blood CXCR5<sup>+</sup>CD4<sup>+</sup> T cells are currently termed blood (or peripheral) memory  $T_{FH}$  cells. Unlike GC  $T_{FH}$  cells, blood memory  $T_{FH}$  cells—even those expressing ICOS and the proliferation marker Ki67—do not express the Bcl-6 protein<sup>54–58</sup>, indicating that Bcl-6 is dispensable for their maintenance. The molecular mechanisms by which blood memory  $T_{FH}$  cells maintain their  $T_{FH}$  characteristics remain largely unknown and thus represent an important research topic.

Human blood memory  $T_{FH}$  cells actually include several populations with unique phenotypes and functions (see ref. 53 for a detailed review). Although staining strategies and markers selected to define blood  $T_{FH}$  subsets differ among laboratories, we propose that blood memory  $T_{FH}$  cells can be assessed on the basis of the following three sets of parameters: the presence of the chemokine receptors CXCR3 and CCR6; of the immunoregulatory molecule PD-1 and the chemokine receptor CCR7; and of the costimulatory molecule ICOS (Fig. 2a).

The first set of parameters defines three major subsets: CXCR3<sup>+</sup>CCR6<sup>-</sup> cells that share properties with  $T_{H1}$  cells (hereinafter called blood memory  $T_{FH1}$  cells), CXCR3<sup>-</sup>CCR6<sup>-</sup> cells resembling  $T_{H2}$  cells (hereinafter called blood memory  $T_{FH2}$  cells) and CXCR3<sup>-</sup>CCR6<sup>+</sup> cells resembling  $T_{H17}$  cells (hereinafter called blood memory  $T_{FH17}$  cells)<sup>55</sup>. Experiments in which isolated T cell subsets were cultured with B cells in the presence of superantigen (such as staphylococcus enterotoxin B to induce cognate interactions between T and B cells) indicated that blood memory  $T_{FH2}$  and  $T_{FH17}$  cells can induce naive B cells to produce immunoglobulins and to switch isotypes through IL-21 secretion. In contrast, blood memory  $T_{FH1}$  cells lack the capacity to help naive B cells<sup>55,59,60</sup>. Furthermore, whereas blood memory  $T_{FH2}$  cells promote IgG and IgE secretion, blood memory  $T_{FH17}$  cells induce IgG and IgA secretion<sup>55</sup>. Thus,  $T_{FH2}$  and

T<sub>FH</sub>17 cells represent efficient B cell helper cells with a distinct capacity to regulate immunoglobulin isotype switching.

The second (PD-1 and CCR7) and third (ICOS) sets of parameters define three other subsets: one activated subset (ICOS<sup>+</sup>PD-1<sup>2+</sup>CCR7<sup>lo</sup>) and two quiescent subsets (ICOS<sup>-</sup>PD-1<sup>+</sup>CCR7<sup>int</sup> and ICOS<sup>-</sup>PD-1<sup>-</sup>CCR7<sup>hi</sup>). In healthy subjects ICOS expression is limited to a small population of blood T<sub>FH</sub> cells; this population substantially increases after vaccination, and thus defines activated memory T<sub>FH</sub> cells. In mice these cells appear before the formation of GC T<sub>FH</sub> cells, because deletion of the *Sh2d1a* gene, encoding the SAP, an adaptor protein essential for the functions of SLAM family receptors, does not affect the formation of this circulating subset but prevents the appearance of terminally differentiated GC T<sub>FH</sub> cells<sup>58</sup>. ICOS<sup>-</sup> cells are further divided into PD-1<sup>+</sup> cells (~30% of blood memory T<sub>FH</sub> cells) and PD-1<sup>-</sup> cells, both of which lack the expression of Ki67 and thus are in a quiescent state<sup>58,59</sup>. CCR7 expression by blood memory T<sub>FH</sub> cells negatively correlates with that of PD-1 (refs. 52,53).

The matrix combination of the three parameters defines nine blood memory T<sub>FH</sub> subsets (Fig. 2a). The activated ICOS<sup>+</sup>PD-1<sup>2+</sup>CCR7<sup>lo</sup> populations within blood memory T<sub>FH</sub>2 and T<sub>FH</sub>17 cells might represent the most efficient helpers. Among quiescent T<sub>FH</sub>2 and T<sub>FH</sub>17 subsets, the ICOS<sup>-</sup>PD-1<sup>+</sup>CCR7<sup>int</sup> population provides help to memory B cells more promptly than the ICOS<sup>-</sup>PD-1<sup>-</sup>CCR7<sup>hi</sup> population<sup>59,60</sup>, but the ICOS<sup>-</sup>PD-1<sup>+</sup>CCR7<sup>int</sup> and ICOS<sup>-</sup>PD-1<sup>-</sup>CCR7<sup>hi</sup> T<sub>FH</sub>2 and T<sub>FH</sub>17 subsets are equally capable of helping naive B cells.

In contrast, blood memory T<sub>FH</sub>1 cells lack the capacity to help naive or memory B cells<sup>54,55,59,60</sup>. Therefore, whether blood memory T<sub>FH</sub>1 cells represent a subset of memory T<sub>FH</sub> cells remains controversial. First, upon T cell receptor stimulation, blood memory T<sub>FH</sub>1 cells produce CXCL13, a chemokine that is highly expressed by GC T<sub>FH</sub> cells and whose receptor, CXCR5, is expressed at high levels by B cells<sup>18,61</sup>. Second, blood memory T<sub>FH</sub>1 cells contain antigen-specific memory cells<sup>59</sup>. Third, upon polyclonal stimulation with the phorbol ester PMA and ionomycin, blood memory T<sub>FH</sub>1 cells produce IL-21 in amounts equivalent to those of blood memory T<sub>FH</sub>2 and T<sub>FH</sub>17 cells<sup>59</sup>. Finally, influenza vaccination transiently induces ICOS expression exclusively on blood memory T<sub>FH</sub>1 cells<sup>54</sup>. The increase in ICOS<sup>+</sup> T<sub>FH</sub>1 cells in blood is positively correlated with the generation of protective antibody responses<sup>54</sup>. Mechanistically, ICOS<sup>+</sup> blood memory T<sub>FH</sub>1 cells help memory, but not naive, B cell differentiation into plasma cells via secretion of IL-21 and IL-10<sup>54</sup>. This observation suggests that blood memory T<sub>FH</sub>1 cells also contribute to antibody responses, but only when they become ICOS<sup>+</sup>PD-1<sup>2+</sup>CCR7<sup>lo</sup> activated cells. Collectively, blood memory T<sub>FH</sub> cells can be subdivided into nonefficient helpers (T<sub>FH</sub>1) and efficient helpers (T<sub>FH</sub>2 and T<sub>FH</sub>17). The differential expression of ICOS, PD-1 and CCR7 further defines developmentally and functionally distinct subpopulations within the subsets.

## T<sub>FH</sub> cells in primary immunodeficiencies

Primary immunodeficiencies are caused by defects in the expression of molecules involved in immune system development and/or function. Analyses of lymphoid tissue and blood samples from patients with primary immunodeficiencies have helped clarify the



requirements for the development of normal immune responses in humans, including the generation of T<sub>FH</sub> cells and GCs. With the success of whole exome sequencing in identifying gene variants responsible for primary immunodeficiencies (at least 34 new gene defects were identified in the past 4 years<sup>62</sup>), investigation of immune responses in affected patients is likely to accelerate understanding of human immunity in the near future.

Patients with ICOS deficiency suffer from common variable immunodeficiency and show severely impaired GC formation in lymphoid tissues and severely decreased blood memory T<sub>FH</sub> cells, accompanied by a severe deficiency of memory B cells<sup>63</sup>. This demonstrates that ICOS is essential for the generation of T<sub>FH</sub> and GC responses in humans, as shown in mice<sup>64</sup>.

Multiple mouse models show that B cells play a fundamental role in the generation of GC T<sub>FH</sub> cells by interacting with T<sub>FH</sub> precursors<sup>25</sup>. This is also the case in humans, as patients with X-linked agammaglobulinemia, who lack mature B cells because of a deficiency of the tyrosine kinase Btk, and those with CVID, who have a significantly reduced number of B cells (<2% in lymphocytes), display significantly reduced frequencies of blood memory T<sub>FH</sub> cells<sup>65</sup>. Patients with hyper IgM syndrome caused by a deficiency of functional CD40L also show severely impaired GC formation, as well as reduced blood memory T<sub>FH</sub> cells<sup>63</sup> and memory B cells<sup>66</sup>, which indicates the importance of CD40-CD40L interactions for GC and T<sub>FH</sub> development in humans, as shown in mice<sup>67</sup>.

SAP-deficient mice show profoundly altered GC reactions and generation of T<sub>FH</sub> cells<sup>68</sup>, as SAP is required for durable interactions between helper T cells and B cells, a process essential for the maturation of T<sub>FH</sub> cells<sup>69</sup>. Consistently, patients with X-linked lymphoproliferative disease caused by SAP deficiency show impaired formation of GCs and impaired development of memory B cells<sup>70</sup>. Interestingly, both SAP-deficient mice and human patients with X-linked lymphoproliferative disease show normal frequencies of blood memory T<sub>FH</sub> cells<sup>58</sup>, suggesting that at least a subset of circulating blood T<sub>FH</sub> cells develop before GC T<sub>FH</sub> formation. Furthermore, migration of GC T<sub>FH</sub> cells into the circulation is limited during the acute phase of the GC response<sup>36,38</sup>. It remains possible that GC T<sub>FH</sub> cells and their descendent memory T<sub>FH</sub> cells in lymphoid organs<sup>39,40</sup> might start circulating during the termination of the GC response.

*In vitro* studies have suggested that IL-12 promotes antibody responses in humans via two mechanisms. IL-12 produced by DCs (CD14<sup>+</sup> dermal DCs in human skin<sup>71</sup>) can induce the *in vitro* differentiation of CD40-activated naive B cells into IgM-producing plasma cells<sup>72,73</sup> and of naive CD4<sup>+</sup> T cells into T<sub>FH</sub>-like cells<sup>74,75</sup>. Consistently, children deficient for the IL-12 receptor  $\beta$ 1 (IL-12R $\beta$ 1) chain, which is shared by the IL-12 and IL-23 receptors, have reduced T<sub>FH</sub> and GC responses<sup>74</sup>. Thus, in addition to the recent *in vitro* observation that TGF- $\beta$  acts as a critical co-factor of IL-12 and IL-23 for the early T<sub>FH</sub> cell differentiation process in humans<sup>46</sup>, impaired T<sub>FH</sub> response in IL-12R $\beta$ 1 deficiency *in vivo* provides evidence that IL-12 and IL-23 contribute to the development of T<sub>FH</sub> responses in humans. Although the frequency of blood memory T<sub>FH</sub> cells is significantly reduced in subjects with IL-12R $\beta$ 1 deficiency during childhood (less than 10 years old), it gradually increases with age and becomes normal in adults. This indicates that the development and/or maintenance

of the T<sub>FH</sub> cell response can be compensated through other pathways and/or cytokines, possibly IL-6, IL-21 and IL-27.

Mutations in the intracellular signaling molecule STAT3 cause most cases of hyper IgE syndrome. People with this syndrome are susceptible to a narrow spectrum of infections linked to defective T<sub>H</sub>17 responses and show altered antibody responses with reduced blood memory T<sub>FH</sub> cells<sup>76,77</sup>, indicating that STAT3 is required for optimal T<sub>FH</sub> cell generation in humans. Given that B cell responses to IL-10 and IL-21, cytokines delivering activation signals via STAT3, are severely altered in STAT3-deficient subjects<sup>78</sup>, the reduced number of blood memory T<sub>FH</sub> cells in STAT3-mutant subjects might be dependent on both B cell–intrinsic and T cell–intrinsic defects. Notably, upon exposure to IL-12, human STAT3 mutant naive CD4<sup>+</sup> T cells are induced to express high amounts of several T<sub>FH</sub> molecules, such as CXCR5, ICOS and Bcl-6, despite lower expression of IL-21 (ref. 76). Thus, other molecules such as STAT4 might functionally compensate for the lack of STAT3. This concept is supported by the finding that STAT3 and STAT4 play largely redundant roles in the expression of T<sub>FH</sub> molecules by human naive CD4<sup>+</sup> T cells exposed to TGF-β<sup>46</sup>.

## T<sub>FH</sub> cells and autoimmunity

The generation of autoantibodies is a hallmark of autoimmune disease. Autoantibodies target a broad range of self-antigens, including nuclear components (such as double-stranded DNA), organ-specific antigens and soluble factors. These autoantibodies can profoundly dysregulate the function of multiple organs or systems through a variety of mechanisms. Autoantibodies result from a breakdown of tolerance mechanisms during B cell development<sup>79</sup>, from T cell–dependent or –independent B cell activation, or as a consequence of somatic mutation and rogue selection within GCs<sup>80,81</sup>. Yet GCs can in some cases redeem self-reactive B cells<sup>82</sup>. There is now compelling evidence in mice and in humans that aberrant generation and/or activation of T<sub>FH</sub> cells and extrafollicular helper T cells contributes to the pathogenesis of autoimmune diseases. Here we first describe evidence of aberrant T<sub>FH</sub> responses in mouse and human autoimmunity, and then discuss how genetic factors are potentially associated with aberrant T<sub>FH</sub> responses in human autoimmune diseases.

## T<sub>FH</sub> cells in autoimmune mouse models

The first evidence linking aberrant T<sub>FH</sub> responses and autoimmunity came from studies of the *sanroque* mouse model, which carries a single-amino-acid mutation known as ‘san’ in the RNA-binding protein Roquin-1 (ref. 16). *Roquin*<sup>san/san</sup> (or *Rc3h1*<sup>san/san</sup>) mice spontaneously develop lupus-like clinical symptoms and, in a genetically susceptible background, type 1 diabetes (T1D). The development of these diseases is accompanied by high amounts of antinuclear and anti-islet antibodies<sup>16,83</sup>. Mechanistically, the mutated Roquin in *Roquin*<sup>san/san</sup> mice displays an impaired ability to repress the expression of *Icos*<sup>16</sup> and *Ifng*<sup>84</sup> in activated helper T cells and promotes the generation of T<sub>FH</sub> cells. *Ox40* (also known as *Tnfrsf4*), a co-stimulatory molecule highly expressed by T<sub>FH</sub> cells<sup>25</sup>, and *Tnf* are additional targets of Roquin and its paralog Roquin-2 (refs. 85–87). T<sub>FH</sub> cells and myeloid cells accumulate and are overactive in *Roquin*<sup>san/san</sup> mice and in mice doubly deficient in



Roquin and Roquin-2 (refs. 86,87). Genetic ablation of *Sh2d1a* (encoding SAP) in *Roquin<sup>san/san</sup>* mice prevents lupus pathology, whereas transfer of *sanroque* T<sub>FH</sub> cells into wild-type mice promotes spontaneous GC formation, supporting a causal role for T<sub>FH</sub> cell accumulation in the lupus-like disease<sup>88</sup>. These findings suggest that excessive T<sub>FH</sub> cells in GCs corrupt positive selection, such as diminished competition for T cell help, and a lower threshold for selection allows the emergence of self-reactive clones. Excessive expression of ICOS<sup>89</sup> and, more prominently, of IFN- $\gamma$ <sup>84</sup> was found to be an important contributor to *Roquin<sup>san</sup>*-mediated T<sub>FH</sub> cell accumulation. Of note, IFN- $\gamma$  signaling blockade has been found not only to alleviate T<sub>FH</sub> and GC B cell accumulation but also to virtually prevent all clinical manifestations associated with *Roquin<sup>san</sup>*-mediated disease, unlike SAP deficiency, which did not correct the splenomegaly or hypergammaglobulinemia<sup>88</sup>, or ICOS deficiency, which did not eliminate autoantibody formation<sup>84</sup>. Other mouse models have also revealed additional mechanisms that cause aberrant T<sub>FH</sub> responses in autoimmune disease. In the BXSB-*Yaa* mouse model, which displays a duplication of the *Tlr7* gene, aberrant T<sub>FH</sub> responses and the development of glomerulonephritis are completely dependent on IL-21 signals<sup>90</sup>, in contrast to what occurs in *Roquin<sup>san/san</sup>* mice, in which IL-21 signals are not essential for pathology<sup>91</sup>. The generation of autoantibodies in the MRL/*lpr* lupus mouse model, which is characterized by deficiency of the proapoptotic molecule Fas, is dependent on the T and B cell interactions at extrafollicular sites<sup>31</sup>. Extrafollicular T<sub>H</sub> cells that develop in MRL/*lpr* mice share features with GC T<sub>FH</sub> cells: their development is dependent on ICOS and Bcl-6, and their helper function is dependent on IL-21 and CD40L<sup>31</sup>. These studies demonstrate that inhibiting the generation of pathogenic T<sub>FH</sub> and extrafollicular helper T cells by blocking ICOS, CD40L, IFN- $\gamma$  or IL-21 ameliorates the generation of autoantibodies and/or the development of glomerulonephritis, thereby providing a rationale for targeting these molecules for therapeutics.

Although T1D has long been thought to be a T cell-driven and organ-specific autoimmune disease, there is now evidence for a pathogenic role for both B cells and antibodies, as well as for T<sub>FH</sub> cell dysregulation, in T1D etiopathogenesis. B cells are required for diabetes development in the nonobese diabetic (NOD) mouse model of T1D<sup>92-94</sup> and in the *Roquin<sup>san/san</sup>* model<sup>83</sup>. Direct evidence for a pathogenic role of autoantibodies comes from experiments demonstrating protection from diabetes in NOD mice made deficient for activating Fc $\gamma$  receptors<sup>95,96</sup> and, conversely, diabetes induction upon passive transfer of antibodies against islet-expressed neo-self-antigens<sup>83,96</sup>. In line with these observations, it is not surprising that correlations are being described between T<sub>FH</sub> cells and autoimmune diabetes. In the *Roquin<sup>san/san</sup>* model, aberrant T<sub>FH</sub> response was directly linked with the development of high anti-islet autoantibody titers and T1D<sup>83</sup>. T<sub>FH</sub> cells were increased in the pancreatic draining lymph nodes of mice that developed autoimmune diabetes<sup>83</sup>, and cells sharing characteristics of T<sub>FH</sub> cells, but expressing CCR9 instead of CXCR5, have been found in the pancreas of diabetic-prone NOD mice<sup>97</sup>.

## T<sub>FH</sub> cells in human autoimmune diseases

Increased GC response in patients with systemic lupus erythematosus (SLE) was suggested in early studies by an increased frequency of CD27<sup>+</sup>CD38<sup>hi</sup> somatically mutated antibody-producing plasmablasts in peripheral blood<sup>98,99</sup>. Because SLE patients display higher

frequencies of self-reactive mature naive B cells than healthy controls owing to a defect in the early checkpoint of B cell repertoires<sup>100,101</sup>, SLE patients seem predisposed to the development of a broader range of autoantibodies than healthy subjects. Whether and how T<sub>FH</sub> cells contribute to the pathogenesis of human autoimmunity has been unclear, but recent progress in understanding the biology of blood memory T<sub>FH</sub> cells has rendered the analysis of human T<sub>FH</sub> responses in the context of autoimmunity feasible.

Since the description of an association between the frequency of CXCR5<sup>+</sup>ICOS<sup>+</sup> and/or CXCR5<sup>+</sup>PD1<sup>+</sup> circulating T<sub>FH</sub> cells and the severity of SLE and Sjögren's syndrome<sup>57</sup>, multiple studies have confirmed<sup>102</sup> or refined these findings, providing improved phenotypic characterization (for example, a reproducible association with the CCR7<sup>lo</sup>PD-1<sup>+/hi</sup> subset<sup>58</sup>), and extended them to additional autoimmune diseases such as myasthenia gravis<sup>103</sup>, rheumatoid arthritis<sup>104,105</sup>, autoimmune thyroid diseases<sup>106</sup> and T1D<sup>107</sup>. An increase of ICOS<sup>+</sup> blood memory T<sub>FH</sub> cells showed a positive correlation with serum autoantibody titers and disease activity and/or severity in these diseases<sup>57,58,104,106–108</sup>. These observations suggest that patients with active autoimmune disease display aberrant T<sub>FH</sub> responses; this can be monitored through assessment of the increase of activated blood memory T<sub>FH</sub> cells.

Accumulating evidence also indicates that patients with autoimmune disease display an alteration in the balance of blood memory T<sub>FH1</sub>, T<sub>FH2</sub> and T<sub>FH17</sub> cells. In patients with juvenile dermatomyositis<sup>55</sup>, adult SLE<sup>109</sup> and Sjögren's syndrome<sup>102</sup>, T<sub>FH1</sub> cells are underrepresented among blood memory T<sub>FH</sub> cells, whereas T<sub>FH2</sub> and/or T<sub>FH17</sub> cells are overrepresented. Such alterations were found to correlate with disease activity, serum autoantibody titers and/or the frequency of blood plasmablasts<sup>55,102,109</sup>. Furthermore, although multiple sclerosis (MS) is not generally considered an autoantibody-mediated autoimmune disease, patients with MS also show the same alteration (low T<sub>FH1</sub> and high T<sub>FH17</sub>) in the composition of blood memory T<sub>FH</sub> subsets<sup>110</sup>. Two additional lines of evidence also support a pathogenic role of T<sub>FH</sub> cells in MS. First, B cells are now thought to play a major pathogenic role in MS, as depletion of B cells with anti-CD20 significantly reduces the number of brain inflammatory lesions and halts the development of new lesions<sup>111</sup>. Second, ectopic B cell follicles are formed in the brain lesions of more than 40% of patients with secondary progressive MS, and the development of these structures correlates with disease severity<sup>112</sup>.

Collectively, although definitive evidence is yet to be found, these observations suggest that an increase in activated T<sub>FH2</sub> and/or T<sub>FH17</sub> cell subsets and a decrease of T<sub>FH1</sub> cells within blood memory T<sub>FH</sub> cells might be common across multiple autoimmune diseases (Fig. 2b). Such alterations in blood memory T<sub>FH</sub> cells might reflect an overall increase of efficient helpers that promote the generation of antibodies in lymphoid organs and/or inflammatory sites in patients with autoimmune diseases. However, to date, studies linking human blood memory T<sub>FH</sub> cells and T<sub>FH</sub> cells in lymphoid organs and/or ectopic GCs in inflammatory tissues are lacking. T<sub>FH</sub> cell responses in ectopic GCs might be of considerable importance, as discussed below.

## T<sub>FH</sub> cells in inflamed tissues

Inflammatory sites in autoimmune diseases often develop lymphoid cell aggregations including helper T cells and B cells, which leads to the formation of well-structured GCs (hereinafter called ectopic GCs). The mechanisms that control the initial development, cellular composition and functional maintenance of ectopic GCs seem to be largely shared with GCs in lymphoid organs<sup>113</sup>. For example, in lupus tubulointerstitial nephritis lesions, T<sub>H</sub> cells found in lymphoid T and B cell aggregates are phenotypically similar to T<sub>FH</sub> cells in lymphoid organs<sup>114</sup>. Although the precise mechanisms by which T<sub>FH</sub> cells accumulate in inflammatory sites in humans remain largely unknown, studies in mouse models suggest the involvement of T<sub>H</sub>17 cells<sup>113</sup>. In the experimental autoimmune encephalomyelitis mouse model, T<sub>H</sub>17 cells induce the formation of ectopic lymphoid follicles in inflammatory brain lesions via IL-17 and the cell surface molecule podoplanin and show features of T<sub>FH</sub> cells in these tertiary lymphoid structures<sup>115</sup>. Given that human patients with autoimmune diseases have increased activated memory T<sub>FH</sub>17 cells in blood (as discussed earlier), that early developmental pathways for T<sub>FH</sub> and T<sub>H</sub>17 cells in inflammatory environments are shared in humans<sup>46</sup>, and that in mice T<sub>H</sub>17-derived IL-17 directly promotes B cell differentiation into GC B cells, which are thought to be the source of pathogenic autoantibodies<sup>116</sup>, it is tempting to speculate that T<sub>FH</sub>17 cells might be involved in the formation of ectopic GCs in human autoimmune diseases.

Among patients with autoimmune disease, those with ectopic GCs in inflammatory lesions often have higher disease activity and are refractory to treatment. Yet the formation of ectopic GCs does not simply reflect the extent or the duration of inflammation in the lesions, as only 20% to 40% of patients with chronic inflammation develop ectopic GCs<sup>113</sup>. The formation of ectopic GCs is preceded by aggregates of T and B cells in inflammatory sites. Therefore, at variance with B cell follicles in lymphoid tissues, where autoreactive B cells are excluded because of their reduced expression of CXCR5 (ref. 117), lymphoid aggregates in inflammatory tissues are likely to be permissive to the entry of autoreactive B cells. Encounters with T<sub>FH</sub>-like cells at these sites<sup>114</sup> might induce their cell growth and/or differentiation into antibody-producing cells. This possibility is directly supported by the observation that B cells in lymphoid aggregates and/or ectopic GCs produce autoantibodies<sup>113</sup>. Moreover, organ-specific self-antigens are easily accessible by antigen-presenting cells, including B cells, because of the abundance of damaged and/or apoptotic cells caused by the inflammatory process. Therefore, ectopic GCs might represent a major site of autoantibody production in autoimmune diseases, and thus a potentially good target for therapeutics. The nature of T<sub>FH</sub> cells in inflamed tissues requires further studies. Questions regarding subjects such as the developmental mechanism of T<sub>FH</sub> cells at inflammatory lesions and how lymphoid aggregates develop into ectopic GCs can be addressed in mouse models, but an effort to determine whether the observations apply to humans will be required. Another important question is whether activated blood memory T<sub>FH</sub> cells present in active autoimmune disease patients originate from inflammatory lesions. It will be critical to answer these questions in order to directly link the information obtained from the analysis of blood T<sub>FH</sub> subsets with autoimmune disease pathogenesis.

## Genetics of altered T<sub>FH</sub> cell response

Autoimmune diseases result from complex interplay between genetic and environmental factors. Genome-wide association studies (GWAS) on multiple autoimmune diseases have yielded risk-associated loci<sup>118</sup> (summary at <http://www.genome.gov/gwastudies>). Variants in HLA class II alleles are at the top of the list of susceptibility loci in most autoantibody-mediated autoimmune diseases, supporting a requirement of CD4<sup>+</sup> helper T cells in disease pathogenesis. Importantly, multiple risk-loci identified in autoimmune diseases are potentially associated with the regulation of the development and/or the function of human T<sub>FH</sub> cells (Fig. 3). The list includes genes associated with IL-12 and IL-23, as well as cytokines implicated in human T<sub>FH</sub> cell differentiation<sup>44,46,74,75</sup>, such as *IL12A*, *IL12B* (both in multiple sclerosis), *IL23R* (rheumatoid arthritis), *STAT3* (multiple sclerosis), *STAT4* (SLE, rheumatoid arthritis, Sjögren's syndrome), *IRF5* (SLE, rheumatoid arthritis) and *IRF8* (SLE, rheumatoid arthritis, multiple sclerosis). The transcription factors IRF5 and IRF8 positively regulate the production of IL-12 and IL-23 by macrophages and DCs<sup>119,120</sup>. IRF8 is essential for IL-12 production in humans. IRF8-deficient human subjects experience disseminated infection caused by bacille Calmette-Guérin vaccines, a clinical manifestation also seen in IL-12 receptor deficiency, due to a profound reduction of IL-12 production by monocytes<sup>119</sup>. IRF8 also contributes to signaling in TGF- $\beta$ , another cytokine important for the generation of human T<sub>FH</sub> cells<sup>46</sup>, by promoting the expression of TGF- $\beta$ -activating integrin  $\alpha_v\beta_8$  on the surface of DCs<sup>121</sup>. Studies in SLE and Sjögren's syndrome suggest that the OX40 ligand (OX40L)-coding *TNFSF4* might be involved in the generation and/or homeostasis of T<sub>FH</sub> cells: overexpression of OX40L causes the accumulation of T cells in B cell follicles<sup>122</sup>, and OX40 receptor signals induce CD4<sup>+</sup> T cells to express CXCR5 in both mice<sup>26,123,124</sup> and humans (unpublished observations). Furthermore, GWAS identified multiple risk-loci encoding molecules expressed by T<sub>FH</sub> cells, including *IL21* (SLE, rheumatoid arthritis) and *CXCR5* (multiple sclerosis, Sjögren's syndrome). A recent study showed that in addition to Blimp-1-encoding *PRDM1* (ref. 22), *PTPN22*, a risk locus identified in GWAS of SLE, rheumatoid arthritis, myasthenia gravis and T1D, negatively regulates the generation of T<sub>FH</sub> and GC responses in mice<sup>125</sup>. However, whether and how most of these gene variants contribute to aberrant T<sub>FH</sub> responses in autoimmune diseases remains unknown. The majority of risk loci consist of single-nucleotide polymorphisms within noncoding, putatively regulatory DNA in the proximity of genes<sup>126</sup>, suggesting either that there is a disease-causing coding mutation in linkage disequilibrium with the GWAS-identified single-nucleotide polymorphism, or that alteration in pre- and/or post-transcriptional regulation is central to dysregulated immune responses in subjects with autoimmune disease traits. Recent studies aimed at mapping genetic variation contributing to transcriptional variation (termed expression quantitative trait locus mapping studies) through the use of purified immune cell subsets have started to reveal how gene variants regulate immune responses in different cell types<sup>126–128</sup>. The integration of expression quantitative trait locus mapping with blood memory T<sub>FH</sub> cells and/or T<sub>FH</sub> cells within inflammatory tissues and antigen-presenting cells obtained from patients with autoimmune disease might reveal how gene variants identified in GWAS contribute to the aberrant T<sub>FH</sub> and GC responses.

## T<sub>FH</sub> cells in cancer

Given the demonstrated mutual dependence of T and B cells for growth and survival, it is not surprising that T<sub>FH</sub> cells play important roles in supporting the growth and survival of follicular B cell tumors. Furthermore, T<sub>FH</sub> cells themselves can give rise to a peripheral T cell tumor known as angioimmunoblastic T cell lymphoma (AITL). Other peripheral T cell tumors also present with phenotypic features and genetic abnormalities that suggest a T<sub>FH</sub> origin. Recently, T<sub>FH</sub> cells were found to infiltrate solid-organ tumors, where they might play both protective and pathogenic roles.

AITL, which accounts for ~20% of peripheral T cell lymphomas (PTCLs), is an aggressive tumor associated with a poor survival rate (33% 5-year survival)<sup>129</sup>. Most patients present with systemic disease associated with lymphadenopathy, hepatosplenomegaly, anemia and hypergammaglobulinemia and suffer from systemic illness. The neoplastic T cells account for only a small fraction of the lymphoid infiltrate and are mixed with a large number of reactive immune cell types, including small lymphocytes, eosinophils and plasma cells, and expansion of follicular dendritic cell networks. Genetic profiling of AITL and immunohistochemical analysis of neoplastic T cells have provided strong evidence that T<sub>FH</sub> cells are the normal cellular counterpart of the neoplastic cells in AITL, which typically express BCL6, CD10 and other T<sub>FH</sub> markers, including CXCL13 and PD-1 (ref. 130). In mice, heterozygosity for a *Roquin-1* mutation that causes T cell–autonomous T<sub>FH</sub> expansion also leads to an AITL-like disease<sup>131</sup>. These mutations have not been found in humans, but mutations in *TET2*, *IDH2*, *DNMT3A* and *RHOA* are commonly found in AITL<sup>132–134</sup>. Although the first three genes are known to play a role in DNA methylation and epigenetic modification of gene expression, how these mutations selectively affect T<sub>FH</sub> cells remains to be understood.

Up to 40% of other PTCLs (PTCLs not otherwise specified (NOS)) also express T<sub>FH</sub> markers, and some share genetic mutations typically found in AITL, including in *TET2*, *IDH2* and *RHOA*. For this reason, these tumors are now being referred to as T<sub>FH</sub>-like PTCL-NOS<sup>135</sup>. The neoplastic T cells of various types of primary cutaneous cell lymphomas also express various T<sub>FH</sub> cell markers, with the exception of CD10, and in some cases also form rosettes with B cells, which typically occurs in AITL<sup>136–139</sup>.

Evidence for a pathogenic role of T<sub>FH</sub> cells in B cell lymphoma first came from studies demonstrating that the number of T cells infiltrating B cell tumors was an important predictor of outcome<sup>140</sup>. Follicular lymphoma, the most frequent indolent non-Hodgkin lymphoma, is thought to originate from GC B cells<sup>141</sup>. The gene expression profiles of tumor-infiltrating T cells and myeloid cells, rather than that of malignant B cells, determine the prognosis for follicular lymphoma<sup>142</sup>. Furthermore, that prognosis worsens if T cells are localized within neoplastic follicles<sup>143</sup>. Tumor-infiltrating T cells have the phenotypic features of T<sub>FH</sub> cells and overexpress IL-4 (ref. 144), TNF, IFN- $\gamma$  and LT- $\alpha$ <sup>145</sup>. In particular, IL-4 produced by tumor-infiltrating T<sub>FH</sub>-like cells causes follicular lymphoma tumor cells to secrete the chemokines CCL17 and CCL22, which attract the migration of T<sub>reg</sub> cells and T<sub>H2</sub> cells<sup>145</sup>. Foxp3<sup>+</sup> T cells that resemble T<sub>FR</sub> cells described in mice are also present in neoplastic follicles and are expanded during lymphomagenesis<sup>146</sup>, although

their significance is still unclear. While overall numbers of tumor-infiltrating Foxp3<sup>+</sup> T cells may be associated with improved survival<sup>147</sup>, their follicular localization may be associated with worse survival and increased risk of transformation<sup>148</sup>, perhaps through the dampening of the cytotoxic T lymphocyte–driven anti-tumor response<sup>149</sup>. Recent reports have described increased circulating T<sub>FH</sub>-like cells in patients with chronic lymphocytic leukemia<sup>150,151</sup>, particularly during the more advanced stages. These expanded T<sub>FH</sub> cells may be of pathological relevance, given that the combination of IL-21 and CD40L induces robust chronic lymphocytic leukemia cell proliferation<sup>150,152</sup>.

In nonlymphoid malignancies, T<sub>FH</sub> cells are a component of the inflammatory infiltrate of breast cancer, and their presence, as assessed by an eight–T<sub>FH</sub> gene signature, was associated with increased survival<sup>153</sup>. Moreover, a single T<sub>FH</sub>-associated gene, CXCL13, conferred the dominant prognostic value. Extensively infiltrated tumors were found to contain tertiary lymphoid structures with visible GCs and CXCL13-producing T<sub>FH</sub> cells. These findings suggest that T<sub>FH</sub> cells, by virtue of their ability to secrete CXCL13 and organize ectopic lymphoid filtrates, may be important in coordinating the recruitment of immune cells that mediate the anti-tumor response.

In other tumor types, a high proportion and altered distribution of T<sub>FH</sub> cells has been reported in colorectal cancer<sup>154</sup> and non–small cell lung cancer<sup>155</sup>. T<sub>FH</sub> cells infiltrate thymomas, correlating with the severity of myasthenia gravis<sup>156</sup>. A recent comprehensive gene analysis study on various immune cells isolated from human colorectal tumors revealed that the infiltration of B cells correlates with the infiltration of T<sub>FH</sub> cells at tumor sites<sup>157</sup> and that the infiltration of B cells and T<sub>FH</sub> cells, which is associated with the expression of *CXCL13* and *IL21*, positively correlates with patient survival. Whether and how T<sub>FH</sub> cells might promote the development of colorectal tumors remains to be established.

## T<sub>FH</sub> cells in HIV and vaccine design

In the past couple of years an intriguing relationship was revealed between T<sub>FH</sub> cells and both human and simian immunodeficiency virus (HIV and SIV, respectively). HIV eliminates the circulating memory CD4<sup>+</sup> T cells it infects, but several groups showed that T<sub>FH</sub> cells accumulate in lymph nodes during chronic SIV<sup>158,159</sup> and HIV<sup>160–163</sup> infection. Furthermore, T<sub>FH</sub> cells expand, despite old<sup>164–166</sup> and new<sup>158,160</sup> evidence that HIV infects T<sub>FH</sub> cells, in which viral replication occurs. Reports from the late 1980s demonstrated that follicular dendritic cell networks in GCs represent a large reservoir of HIV virions<sup>167</sup>, retained as immune complexes<sup>163</sup>. Thus, T<sub>FH</sub> cells are constantly exposed to the virus during chronic infection. In contrast to the T<sub>FH</sub> cell accumulation seen in lymph nodes, blood memory PD-1<sup>+</sup> T<sub>FH</sub>17 cells capable of providing help to B cells are decreased in chronic HIV infection, but they recover after antiretroviral therapy<sup>60</sup>.

The relationships among viral load, chronicity and numbers of T<sub>FH</sub> cells are complex. Although most studies have failed to identify a correlation between lymph node T<sub>FH</sub> cell numbers and viral load<sup>158,159,161</sup>, there are possible explanations for the reduction in T<sub>FH</sub> cells after antiretroviral therapy<sup>160,162</sup>: the antigen load might control the total number of



T<sub>FH</sub> cells, the compartmentalization of T<sub>FH</sub> cells between secondary lymphoid tissues and the circulation, or the survival of the blood memory T<sub>FH</sub> cells. Further work is clearly needed to explain the mechanisms behind these findings.

Chronic HIV infection is associated with an increased frequency of T<sub>FH</sub> cells in lymph nodes together with increased expression of Bcl-6 (ref. 158). The expression of IL-6 receptor on T<sub>FH</sub> cells is increased, which might mediate increased responsiveness to IL-6 (ref. 158). The importance of IL-6 signals for the maintenance of the T<sub>FH</sub> response in chronic infection is also highlighted in a mouse model of chronic viral infection with LCMV clone 13 (ref. 168). Increased T<sub>FH</sub> generation during chronic HIV infection may in turn affect the host's immune response not only against HIV, but also against other, unrelated viral and bacterial infections<sup>169</sup>. High T<sub>FH</sub> numbers in HIV-infected individuals correlate with B cell dysregulation, including hypergammaglobulinemia, loss of memory B cells and, occasionally, production of autoantibodies and development of autoimmunity<sup>170</sup>. It is possible that the lowered threshold of B cell selection in GCs due to an excess of T<sub>FH</sub> cells<sup>171</sup> might lead to the generation of antibodies with low affinities. Alternatively, T<sub>FH</sub> cell function might be dampened by either T cell-intrinsic factors (e.g., increased sensitivity to IL-6 signaling)<sup>158</sup> or the microenvironment (e.g., increased PD-L1 expression by GC B cells that dampens IL-21 production by T<sub>FH</sub> cells<sup>162</sup>).

Designing potent HIV vaccines remains a major challenge. It is now established that antibodies can be protective and prevent infection, as passive transfer of broadly neutralizing antibodies confers protection to HIV challenge in humanized mice infected with HIV<sup>172,173</sup>. However, most vaccine trials have failed to protect vaccinated individuals to any significant degree. A number of factors associated with HIV make the creation of a decently protective antibody-based vaccine difficult, such as fast mutation rates, structural properties of the envelope complex that make conserved epitopes relatively inaccessible to antibodies, and the need for B cells to undergo extensive somatic mutation to generate broadly neutralizing antibodies. The recent HIV vaccine RV144 "Thai" trial showed that binding of IgG antibodies to envelope proteins is associated with protection, whereas binding of IgA antibodies to envelope proteins correlates directly with the rate of infection<sup>174</sup>. These data suggest a need to better understand the nature and isotype of the antibody response to be elicited by vaccines for protection. There is encouraging evidence that numbers of blood ICOS<sup>+</sup>PD1<sup>+</sup> T<sub>FH2</sub> and T<sub>FH17</sub> cells (but not T<sub>FH1</sub> cells) may serve as a useful biomarker for patients producing broadly neutralizing antibodies to HIV<sup>175</sup>. However, the significant overlap in measurements between high- and low-affinity groups calls for additional studies to further delineate the best correlates of protection. Although numerous studies have concluded that a potent T<sub>FH</sub> response correlates with antibody titers and protective responses<sup>54,58,59</sup>, there is also evidence that an excessive response might be deleterious. Thus, limiting of T<sub>FH</sub> cells is required for optimal affinity maturation<sup>176</sup>, and an excessive number of T<sub>FH</sub> cells lowers the threshold for positive selection, allowing survival of low-affinity and self-reactive clones<sup>88</sup>. Furthermore, the balance between T<sub>FH</sub> and T<sub>FR</sub> cells is also likely to be important for the overall duration and quality control of GC responses<sup>34</sup>. So far, very little is known about how different adjuvants and prime-boost regime strategies influence the magnitude, longevity and quality of antibody responses. This knowledge will be important for the improved and rational design of protective vaccines.

## Conclusions

In the past 5 years considerable progress has been made in the understanding of T<sub>FH</sub> cells, particularly in humans. We predict that this progress will lead to improved vaccine designs, better management of autoimmune diseases and novel prognostic biomarkers for lymphoid and solid tumors.

## ACKNOWLEDGMENTS

Supported by the US National Institutes of Health (U19-AI057234, U19-AI082715 and U19-AI089987), the Alliance for Lupus Research, the Baylor Health Care System (H.U.) and the Australian National Health and Medical Research Council (C.G.V.).

## References

1. Miller JF, Mitchell GF. Cell to cell interaction in the immune response. I. Hemolysin-forming cells in neonatally thymectomized mice reconstituted with thymus or thoracic duct lymphocytes. *J. Exp. Med.* 1968; 128:801–820. [PubMed: 5691985]
2. MacLennan IC. Germinal centers. *Annu. Rev. Immunol.* 1994; 12:117–139. [PubMed: 8011279]
3. Allen CD, Okada T, Cyster JG. Germinal-center organization and cellular dynamics. *Immunity.* 2007; 27:190–202. [PubMed: 17723214]
4. Victora GD, Nussenzweig MC. Germinal centers. *Annu. Rev. Immunol.* 2012; 30:429–457. [PubMed: 22224772]
5. Banchereau J, et al. The CD40 antigen and its ligand. *Annu. Rev. Immunol.* 1994; 12:881–922. [PubMed: 7516669]
6. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. *Annu. Rev. Immunol.* 1989; 7:145–173. [PubMed: 2523712]
7. Dobner T, Wolf I, Emrich T, Lipp M. Differentiation-specific expression of a novel G protein-coupled receptor from Burkitt's lymphoma. *Eur. J. Immunol.* 1992; 22:2795–2799. [PubMed: 1425907]
8. Förster R, et al. A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. *Cell.* 1996; 87:1037–1047. [PubMed: 8978608]
9. Ansel KM, McHeyzer-Williams LJ, Ngo VN, McHeyzer-Williams MG, Cyster JG. *In vivo*-activated CD4 T cells upregulate CXC chemokine receptor 5 and reprogram their response to lymphoid chemokines. *J. Exp. Med.* 1999; 190:1123–1134. [PubMed: 10523610]
10. Breitfeld D, et al. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. *J. Exp. Med.* 2000; 192:1545–1552. [PubMed: 11104797]
11. Schaerli P, et al. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. *J. Exp. Med.* 2000; 192:1553–1562. [PubMed: 11104798]
12. Kim CH, et al. Subspecialization of CXCR5+ T cells: B helper activity is focused in a germinal center-localized subset of CXCR5+ T cells. *J. Exp. Med.* 2001; 193:1373–1381. [PubMed: 11413192]
13. Campbell DJ, Kim CH, Butcher EC. Separable effector T cell populations specialized for B cell help or tissue inflammation. *Nat. Immunol.* 2001; 2:876–881. [PubMed: 11526405]
14. Chtanova T, et al. T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1/Th2 effector cells that provide help for B cells. *J. Immunol.* 2004; 173:68–78. [PubMed: 15210760]
15. Rasheed AU, Rahn HP, Sallusto F, Lipp M, Muller G. Follicular B helper T cell activity is confined to CXCR5(hi)ICOS(hi) CD4 T cells and is independent of CD57 expression. *Eur. J. Immunol.* 2006; 36:1892–1903. [PubMed: 16791882]

16. Vinuesa CG, et al. A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. *Nature*. 2005; 435:452–458. [PubMed: 15917799]
17. Bryant VL, et al. Cytokine-mediated regulation of human B cell differentiation into Ig-secreting cells: predominant role of IL-21 produced by CXCR5+ T follicular helper cells. *J. Immunol*. 2007; 179:8180–8190. [PubMed: 18056361]
18. Bentebibel SE, Schmitt N, Banchereau J, Ueno H. Human tonsil B-cell lymphoma 6 (BCL6)-expressing CD4+ T-cell subset specialized for B-cell help outside germinal centers. *Proc. Natl. Acad. Sci. USA*. 2011; 108:E488–E497. [PubMed: 21808017]
19. Han S, et al. Cellular interaction in germinal centers. Roles of CD40 ligand and B7-2 in established germinal centers. *J. Immunol*. 1995; 155:556–567. [PubMed: 7541819]
20. Casamayor-Palleja M, Khan M, MacLennan IC. A subset of CD4+ memory T cells contains preformed CD40 ligand that is rapidly but transiently expressed on their surface after activation through the T cell receptor complex. *J. Exp. Med*. 1995; 181:1293–1301. [PubMed: 7699321]
21. Nurieva RI, et al. Bcl6 mediates the development of T follicular helper cells. *Science*. 2009; 325:1001–1005. [PubMed: 19628815]
22. Johnston RJ, et al. Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. *Science*. 2009; 325:1006–1010. [PubMed: 19608860]
23. Yu D, et al. The transcriptional repressor Bcl-6 directs T follicular helper cell lineage commitment. *Immunity*. 2009; 31:457–468. [PubMed: 19631565]
24. Tangye SG, Ma CS, Brink R, Deenick EK. The good, the bad and the ugly—TFH cells in human health and disease. *Nat. Rev. Immunol*. 2013; 13:412–426. [PubMed: 23681096]
25. Crotty S. Follicular helper CD4 T cells (TFH). *Annu. Rev. Immunol*. 2011; 29:621–663. [PubMed: 21314428]
26. Flynn S, Toellner KM, Raykundalia C, Goodall M, Lane P. CD4 T cell cytokine differentiation: the B cell activation molecule, OX40 ligand, instructs CD4 T cells to express interleukin 4 and upregulates expression of the chemokine receptor, Blnr-1. *J. Exp. Med*. 1998; 188:297–304. [PubMed: 9670042]
27. Kerfoot SM, et al. Germinal center B cell and T follicular helper cell development initiates in the interfollicular zone. *Immunity*. 2011; 34:947–960. [PubMed: 21636295]
28. Kitano M, et al. Bcl6 protein expression shapes pre-germinal center B cell dynamics and follicular helper T cell heterogeneity. *Immunity*. 2011; 34:961–972. [PubMed: 21636294]
29. Liu X, et al. Transcription factor achaete-scute homologue 2 initiates follicular T-helper-cell development. *Nature*. 2014; 507:513–518. [PubMed: 24463518]
30. Haynes NM, et al. Role of CXCR5 and CCR7 in follicular Th cell positioning and appearance of a programmed cell death gene-1high germinal center-associated subpopulation. *J. Immunol*. 2007; 179:5099–5108. [PubMed: 17911595]
31. Odegard JM, et al. ICOS-dependent extrafollicular helper T cells elicit IgG production via IL-21 in systemic autoimmunity. *J. Exp. Med*. 2008; 205:2873–2886. [PubMed: 18981236]
32. Garside P, et al. Visualization of specific B and T lymphocyte interactions in the lymph node. *Science*. 1998; 281:96–99. [PubMed: 9651253]
33. Lee SK, et al. B cell priming for extrafollicular antibody responses requires Bcl-6 expression by T cells. *J. Exp. Med*. 2011; 208:1377–1388. [PubMed: 21708925]
34. Ramiscal RR, Vinuesa CG. T-cell subsets in the germinal center. *Immunol. Rev*. 2013; 252:146–155. [PubMed: 23405902]
35. Lüthje K, et al. The development and fate of follicular helper T cells defined by an IL-21 reporter mouse. *Nat. Immunol*. 2012; 13:491–498. [PubMed: 22466669]
36. Shulman Z, et al. T follicular helper cell dynamics in germinal centers. *Science*. 2013; 341:673–677. [PubMed: 23887872]
37. Moriyama S, et al. Sphingosine-1-phosphate receptor 2 is critical for follicular helper T cell retention in germinal centers. *J. Exp. Med*. 2014; 211:1297–1305. [PubMed: 24913235]
38. Shulman Z, et al. Dynamic signaling by T follicular helper cells during germinal center B cell selection. *Science*. 2014; 345:1058–1062. [PubMed: 25170154]

39. Wollenberg I, et al. Regulation of the germinal center reaction by Foxp3<sup>+</sup> follicular regulatory T cells. *J. Immunol.* 2011; 187:4553–4560. [PubMed: 21984700]
40. Linterman MA, et al. Foxp3<sup>+</sup> follicular regulatory T cells control the germinal center response. *Nat. Med.* 2011; 17:975–982. [PubMed: 21785433]
41. Chung Y, et al. Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions. *Nat. Med.* 2011; 17:983–988. [PubMed: 21785430]
42. Porwit-Ksiazek A, Ksiazek T, Biberfeld P. Leu 7<sup>+</sup> (HNK-1<sup>+</sup>) cells. I. Selective compartmentalization of Leu 7<sup>+</sup> cells with different immunophenotypes in lymphatic tissues and blood. *Scand. J. Immunol.* 1983; 18:485–493. [PubMed: 6198715]
43. Velardi A, Mingari MC, Moretta L, Grossi CE. Functional analysis of cloned germinal center CD4<sup>+</sup> cells with natural killer cell-related features. Divergence from typical T helper cells. *J. Immunol.* 1986; 137:2808–2813. [PubMed: 2944964]
44. Ma CS, et al. Early commitment of naive human CD4(+) T cells to the T follicular helper (TFH) cell lineage is induced by IL-12. *Immunol. Cell Biol.* 2009; 87:590–600. [PubMed: 19721453]
45. Fazilleau N, McHeyzer-Williams LJ, Rosen H, McHeyzer-Williams MG. The function of follicular helper T cells is regulated by the strength of T cell antigen receptor binding. *Nat. Immunol.* 2009; 10:375–384. [PubMed: 19252493]
46. Schmitt N, et al. The cytokine TGF- $\beta$  co-opts signaling via STAT3-STAT4 to promote the differentiation of human TFH cells. *Nat. Immunol.* 2014; 15:856–865. [PubMed: 25064073]
47. Nakayama S, et al. Early Th1 cell differentiation is marked by a Tfh cell-like transition. *Immunity.* 2011; 35:919–931. [PubMed: 22195747]
48. Bauquet AT, et al. The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells. *Nat. Immunol.* 2009; 10:167–175. [PubMed: 19098919]
49. Nurieva RI, et al. Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. *Immunity.* 2008; 29:138–149. [PubMed: 18599325]
50. Suto A, et al. Development and characterization of IL-21-producing CD4<sup>+</sup> T cells. *J. Exp. Med.* 2008; 205:1369–1379. [PubMed: 18474630]
51. Förster R, Emrich T, Kremmer E, Lipp M. Expression of the G-protein-coupled receptor BLR1 defines mature, recirculating B cells and a subset of T-helper memory cells. *Blood.* 1994; 84:830–840. [PubMed: 7913842]
52. Schaerli P, Loetscher P, Moser B. Cutting edge: induction of follicular homing precedes effector Th cell development. *J. Immunol.* 2001; 167:6082–6086. [PubMed: 11714765]
53. Schmitt N, Bentebibel SE, Ueno H. Phenotype and functions of memory Tfh cells in human blood. *Trends Immunol.* 2014; 35:436–442. [PubMed: 24998903]
54. Bentebibel SE, et al. Induction of ICOS<sup>+</sup>CXCR3<sup>+</sup>CXCR5<sup>+</sup> TH cells correlates with antibody responses to influenza vaccination. *Sci. Transl. Med.* 2013; 5:176ra132.
55. Morita R, et al. Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. *Immunity.* 2011; 34:108–121. [PubMed: 21215658]
56. Chevalier N, et al. CXCR5 expressing human central memory CD4 T cells and their relevance for humoral immune responses. *J. Immunol.* 2011; 186:5556–5568. [PubMed: 21471443]
57. Simpson N, et al. Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. *Arthritis Rheum.* 2010; 62:234–244. [PubMed: 20039395]
58. He J, et al. Circulating precursor CCR7(lo)PD-1(hi) CXCR5(+) CD4(+) T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure. *Immunity.* 2013; 39:770–781. [PubMed: 24138884]
59. Locci M, et al. Human circulating PD-1(+)/CXCR3(-)CXCR5(+) memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. *Immunity.* 2013; 39:758–769. [PubMed: 24035365]
60. Boswell KL, et al. Loss of circulating CD4 T cells with B cell helper function during chronic HIV infection. *PLoS Pathog.* 2014; 10:e1003853. [PubMed: 24497824]

61. Kim CH, et al. Unique gene expression program of human germinal center T helper cells. *Blood*. 2004; 104:1952–1960. [PubMed: 15213097]
62. Conley ME, Casanova JL. Discovery of single-gene inborn errors of immunity by next generation sequencing. *Curr. Opin. Immunol.* 2014; 30:17–23. [PubMed: 24886697]
63. Bossaller L, et al. ICOS deficiency is associated with a severe reduction of CXCR5+CD4 germinal center Th cells. *J. Immunol.* 2006; 177:4927–4932. [PubMed: 16982935]
64. Akiba H, et al. The role of ICOS in the CXCR5+ follicular B helper T cell maintenance *in vivo*. *J. Immunol.* 2005; 175:2340–2348. [PubMed: 16081804]
65. Martini H, et al. Importance of B cell co-stimulation in CD4(+) T cell differentiation: X-linked agammaglobulinaemia, a human model. *Clin. Exp. Immunol.* 2011; 164:381–387. [PubMed: 21488866]
66. Lougaris V, Badolato R, Ferrari S, Plebani A. Hyper immunoglobulin M syndrome due to CD40 deficiency: clinical, molecular, and immunological features. *Immunol. Rev.* 2005; 203:48–66. [PubMed: 15661021]
67. Kawabe T, et al. The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. *Immunity*. 1994; 1:167–178. [PubMed: 7534202]
68. Crotty S, Kersh EN, Cannons J, Schwartzberg PL, Ahmed R. SAP is required for generating long-term humoral immunity. *Nature*. 2003; 421:282–287. [PubMed: 12529646]
69. Qi H, Cannons JL, Klauschen F, Schwartzberg PL, Germain RN. SAP-controlled T-B cell interactions underlie germinal centre formation. *Nature*. 2008; 455:764–769. [PubMed: 18843362]
70. Cannons JL, Tangye SG, Schwartzberg PL. SLAM family receptors and SAP adaptors in immunity. *Annu. Rev. Immunol.* 2011; 29:665–705. [PubMed: 21219180]
71. Klechevsky E, et al. Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. *Immunity*. 2008; 29:497–510. [PubMed: 18789730]
72. Caux C, et al. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha: II. Functional analysis. *Blood*. 1997; 90:1458–1470. [PubMed: 9269763]
73. Dubois B, et al. Critical role of IL-12 in dendritic cell-induced differentiation of naive B lymphocytes. *J. Immunol.* 1998; 161:2223–2231. [PubMed: 9725215]
74. Schmitt N, et al. IL-12 receptor beta1 deficiency alters *in vivo* T follicular helper cell response in humans. *Blood*. 2013; 121:3375–3385. [PubMed: 23476048]
75. Schmitt N, et al. Human dendritic cells induce the differentiation of interleukin-21-producing T follicular helper-like cells through interleukin-12. *Immunity*. 2009; 31:158–169. [PubMed: 19592276]
76. Ma CS, et al. Functional STAT3 deficiency compromises the generation of human T follicular helper cells. *Blood*. 2012; 119:3997–4008. [PubMed: 22403255]
77. Mazerolles F, Picard C, Kracker S, Fischer A, Durandy A. Blood CD4+CD45RO+CXCR5+ T cells are decreased but partially functional in signal transducer and activator of transcription 3 deficiency. *J. Allergy Clin. Immunol.* 2013; 131:1146–1156. e1141–e1145. [PubMed: 23403044]
78. Avery DT, et al. B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. *J. Exp. Med.* 2010; 207:155–171. S151–S155. [PubMed: 20048285]
79. Yurasov S, Nussenzweig MC. Regulation of autoreactive antibodies. *Curr. Opin. Rheumatol.* 2007; 19:421–426. [PubMed: 17762605]
80. Di Zenzo G, et al. Pemphigus autoantibodies generated through somatic mutations target the desmoglein-3 cis-interface. *J. Clin. Invest.* 2012; 122:3781–3790. [PubMed: 22996451]
81. Vinuesa CG, Sanz I, Cook MC. Dysregulation of germinal centres in autoimmune disease. *Nat. Rev. Immunol.* 2009; 9:845–857. [PubMed: 19935804]
82. Sabouri Z, et al. Redemption of autoantibodies on anergic B cells by variable-region glycosylation and mutation away from self-reactivity. *Proc. Natl. Acad. Sci. USA.* 2014; 111:E2567–E2575. [PubMed: 24821781]

83. Silva DG, et al. Anti-islet autoantibodies trigger autoimmune diabetes in the presence of an increased frequency of islet-reactive CD4 T cells. *Diabetes*. 2011; 60:2102–2111. [PubMed: 21788582]
84. Lee SK, et al. Interferon-gamma excess leads to pathogenic accumulation of follicular helper T cells and germinal centers. *Immunity*. 2012; 37:880–892. [PubMed: 23159227]
85. Leppik K, et al. Roquin promotes constitutive mRNA decay via a conserved class of stem-loop recognition motifs. *Cell*. 2013; 153:869–881. [PubMed: 23663784]
86. Pratama A, et al. Roquin-2 shares functions with its paralog Roquin-1 in the repression of mRNAs controlling T follicular helper cells and systemic inflammation. *Immunity*. 2013; 38:669–680. [PubMed: 23583642]
87. Vogel KU, et al. Roquin paralogs 1 and 2 redundantly repress the Icos and Ox40 costimulator mRNAs and control follicular helper T cell differentiation. *Immunity*. 2013; 38:655–668. [PubMed: 23583643]
88. Linterman MA, et al. Follicular helper T cells are required for systemic autoimmunity. *J. Exp. Med.* 2009; 206:561–576. [PubMed: 19221396]
89. Yu D, et al. Roquin represses autoimmunity by limiting inducible T-cell co-stimulator messenger RNA. *Nature*. 2007; 450:299–303. [PubMed: 18172933]
90. Bubier JA, et al. A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXS<sup>B</sup>-Yaa mice. *Proc. Natl. Acad. Sci. USA*. 2009; 106:1518–1523. [PubMed: 19164519]
91. Linterman MA, et al. Roquin differentiates the specialized functions of duplicated T cell costimulatory receptor genes CD28 and ICOS. *Immunity*. 2009; 30:228–241. [PubMed: 19217324]
92. Serreze DV, et al. B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new “speed congenic” stock of NOD.Ig mu null mice. *J. Exp. Med.* 1996; 184:2049–2053. [PubMed: 8920894]
93. Akashi T, et al. Direct evidence for the contribution of B cells to the progression of insulinitis and the development of diabetes in non-obese diabetic mice. *Int. Immunol.* 1997; 9:1159–1164. [PubMed: 9263013]
94. Noorchashm H, et al. B-cells are required for the initiation of insulinitis and sialitis in nonobese diabetic mice. *Diabetes*. 1997; 46:941–946. [PubMed: 9166663]
95. Inoue Y, et al. Activating Fc gamma receptors participate in the development of autoimmune diabetes in NOD mice. *J. Immunol.* 2007; 179:764–774. [PubMed: 17617565]
96. Harbers SO, et al. Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance. *J. Clin. Invest.* 2007; 117:1361–1369. [PubMed: 17446931]
97. McGuiire HM, et al. A subset of interleukin-21+ chemokine receptor CCR9+ T helper cells target accessory organs of the digestive system in autoimmunity. *Immunity*. 2011; 34:602–615. [PubMed: 21511186]
98. Arce E, et al. Increased frequency of pre-germinal center b cells and plasma cell precursors in the blood of children with systemic lupus erythematosus. *J. Immunol.* 2001; 167:2361–2369. [PubMed: 11490026]
99. Jacobi AM, et al. Correlation between circulating CD27<sup>high</sup> plasma cells and disease activity in patients with systemic lupus erythematosus. *Arthritis Rheum.* 2003; 48:1332–1342. [PubMed: 12746906]
100. Yurasov S, et al. Persistent expression of autoantibodies in SLE patients in remission. *J. Exp. Med.* 2006; 203:2255–2261. [PubMed: 16966430]
101. Yurasov S, et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. *J. Exp. Med.* 2005; 201:703–711. [PubMed: 15738055]
102. Li XY, et al. Role of the frequency of blood CD4(+) CXCR5(+) CCR6(+) T cells in autoimmunity in patients with Sjogren’s syndrome. *Biochem. Biophys. Res. Commun.* 2012; 422:238–244. [PubMed: 22575453]
103. Luo C, et al. Expansion of circulating counterparts of follicular helper T cells in patients with myasthenia gravis. *J. Neuroimmunol.* 2013; 256:55–61. [PubMed: 23305745]




104. Wang J, et al. High frequencies of activated B cells and T follicular helper cells are correlated with disease activity in patients with new-onset rheumatoid arthritis. *Clin. Exp. Immunol.* 2013; 174:212–220. [PubMed: 23786438]
105. Liu R, et al. A regulatory effect of IL-21 on T follicular helper-like cell and B cell in rheumatoid arthritis. *Arthritis Res. Ther.* 2012; 14:R255. [PubMed: 23176102]
106. Zhu C, et al. Increased frequency of follicular helper T cells in patients with autoimmune thyroid disease. *J. Clin. Endocrinol. Metab.* 2012; 97:943–950. [PubMed: 22188745]
107. Xu X, et al. Inhibition of increased circulating Tfh cell by anti-CD20 monoclonal antibody in patients with type 1 diabetes. *PLoS ONE.* 2013; 8:e79858. [PubMed: 24278195]
108. Luo C, et al. Expansion of circulating counterparts of follicular helper T cells in patients with myasthenia gravis. *J. Neuroimmunol.* 2013; 256:55–61. [PubMed: 23305745]
109. Le Coz C, et al. Circulating TFH subset distribution is strongly affected in lupus patients with an active disease. *PLoS ONE.* 2013; 8:e75319. [PubMed: 24069401]
110. Romme Christensen J, et al. Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression. *PLoS ONE.* 2013; 8:e57820. [PubMed: 23469245]
111. Hauser SL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. *N. Engl. J. Med.* 2008; 358:676–688. [PubMed: 18272891]
112. Magliozzi R, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. *Brain.* 2007; 130:1089–1104. [PubMed: 17438020]
113. Pitzalis C, Jones GW, Bombardieri M, Jones SA. Ectopic lymphoid-like structures in infection, cancer and autoimmunity. *Nat. Rev. Immunol.* 2014; 14:447–462. [PubMed: 24948366]
114. Liarski VM, et al. Cell distance mapping identifies functional T follicular helper cells in inflamed human renal tissue. *Sci. Transl. Med.* 2014; 6:230ra246.
115. Peters A, et al. Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. *Immunity.* 2011; 35:986–996. [PubMed: 22177922]
116. Wu HJ, et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. *Immunity.* 2010; 32:815–827. [PubMed: 20620945]
117. Ekland EH, Forster R, Lipp M, Cyster JG. Requirements for follicular exclusion and competitive elimination of autoantigen-binding B cells. *J. Immunol.* 2004; 172:4700–4708. [PubMed: 15067045]
118. Stranger BE, De Jager PL. Coordinating GWAS results with gene expression in a systems immunologic paradigm in autoimmunity. *Curr. Opin. Immunol.* 2012; 24:544–551. [PubMed: 23040211]
119. Hambleton S, et al. IRF8 mutations and human dendritic-cell immunodeficiency. *N. Engl. J. Med.* 2011; 365:127–138. [PubMed: 21524210]
120. Krausgruber T, et al. IRF5 promotes inflammatory macrophage polarization and TH1–TH17 responses. *Nat. Immunol.* 2011; 12:231–238. [PubMed: 21240265]
121. Yoshida Y, et al. The transcription factor IRF8 activates integrin-mediated TGF-beta signaling and promotes neuroinflammation. *Immunity.* 2014; 40:187–198. [PubMed: 24485804]
122. Brouwer T, et al. CD4 T cell traffic control: *in vivo* evidence that ligation of OX40 on CD4 T cells by OX40-ligand expressed on dendritic cells leads to the accumulation of CD4 T cells in B follicles. *Eur. J. Immunol.* 1999; 29:1610–1616. [PubMed: 10359115]
123. Walker LS, et al. Compromised OX40 function in CD28-deficient mice is linked with failure to develop CXC chemokine receptor 5-positive CD4 cells and germinal centers. *J. Exp. Med.* 1999; 190:1115–1122. [PubMed: 10523609]
124. Kim MY, et al. CD4(+)/CD3(–) accessory cells costimulate primed CD4 T cells through OX40 and CD30 at sites where T cells collaborate with B cells. *Immunity.* 2003; 18:643–654. [PubMed: 12753741]
125. Maine CJ, Marquardt K, Cheung J, Sherman LA. PTPN22 controls the germinal center by influencing the numbers and activity of T follicular helper cells. *J. Immunol.* 2014; 192:1415–1424. [PubMed: 24453256]

126. Okada Y, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. *Nature*. 2014; 506:376–381. [PubMed: 24390342]
127. Fairfax BP, et al. Innate immune activity conditions the effect of regulatory variants upon monocyte gene expression. *Science*. 2014; 343:1246949. [PubMed: 24604202]
128. Raj T, et al. Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. *Science*. 2014; 344:519–523. [PubMed: 24786080]
129. Federico M, et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. *J. Clin. Oncol.* 2013; 31:240–246. [PubMed: 22869878]
130. de Leval L, Gisselbrecht C, Gaulard P. Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. *Br. J. Haematol.* 2010; 148:673–689. [PubMed: 19961485]
131. Ellyard JI, et al. Heterozygosity for Roquinsan leads to angioimmunoblastic T-cell lymphoma-like tumors in mice. *Blood*. 2012; 120:812–821. [PubMed: 22700722]
132. Sakata-Yanagimoto M, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. *Nat. Genet.* 2014; 46:171–175. [PubMed: 24413737]
133. Odejide O, et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. *Blood*. 2014; 123:1293–1296. [PubMed: 24345752]
134. Yoo HY, et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. *Nat. Genet.* 2014; 46:371–375. [PubMed: 24584070]
135. Lemonnier F, et al. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. *Blood*. 2012; 120:1466–1469. [PubMed: 22760778]
136. Cetinözman F, Jansen PM, Willemze R. Expression of programmed death-1 in primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma, cutaneous pseudo-T-cell lymphoma, and other types of cutaneous T-cell lymphoma. *Am. J. Surg. Pathol.* 2012; 36:109–116. [PubMed: 21989349]
137. Meyerson HJ, et al. Follicular center helper T-cell (TFH) marker positive mycosis fungoides/Sezary syndrome. *Mod. Pathol.* 2013; 26:32–43. [PubMed: 22918164]
138. Rodríguez Pinilla SM, et al. Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma expresses follicular T-cell markers. *Am. J. Surg. Pathol.* 2009; 33:81–90. [PubMed: 18987541]
139. Park JH, Han JH, Kang HY, Lee ES, Kim YC. Expression of follicular helper T-cell markers in primary cutaneous T-cell lymphoma. *Am. J. Dermatopathol.* 2014; 36:465–470. [PubMed: 24162385]
140. Lee AM, et al. Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. *J. Clin. Oncol.* 2006; 24:5052–5059. [PubMed: 17033038]
141. Shaffer AL, Rosenwald A, Staudt LM. Lymphoid malignancies: the dark side of B-cell differentiation. *Nat. Rev. Immunol.* 2002; 2:920–932. [PubMed: 12461565]
142. Dave SS, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. *N. Engl. J. Med.* 2004; 351:2159–2169. [PubMed: 15548776]
143. Glas AM, et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. *J. Clin. Oncol.* 2007; 25:390–398. [PubMed: 17200149]
144. Pangault C, et al. Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent T(FH)-B cell axis. *Leukemia*. 2010; 24:2080–2089. [PubMed: 20944673]
145. Rawal S, et al. Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment. *J. Immunol.* 2013; 190:6681–6693. [PubMed: 23686488]
146. Amé-Thomas P, et al. Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells. *Leukemia*. 2012; 26:1053–1063. [PubMed: 22015774]


147. Carreras J, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. *Blood*. 2006; 108:2957–2964. [PubMed: 16825494]
148. Farinha P, et al. The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. *Blood*. 2010; 115:289–295. [PubMed: 19901260]
149. Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM. Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma. *Cancer Res*. 2006; 66:10145–10152. [PubMed: 17047079]
150. Ahearn MJ, et al. Enhancement of CD154/IL4 proliferation by the T follicular helper (Tfh) cytokine, IL21 and increased numbers of circulating cells resembling Tfh cells in chronic lymphocytic leukaemia. *Br. J. Haematol*. 2013; 162:360–370. [PubMed: 23710828]
151. Cha Z, et al. Association of peripheral CD4+ CXCR5+ T cells with chronic lymphocytic leukemia. *Tumour Biol*. 2013; 34:3579–3585. [PubMed: 23807677]
152. Pascutti MF, et al. IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells. *Blood*. 2013; 122:3010–3019. [PubMed: 24014238]
153. Gu-Trantien C, et al. CD4(+) follicular helper T cell infiltration predicts breast cancer survival. *J. Clin. Invest*. 2013; 123:2873–2892. [PubMed: 23778140]
154. Wang Z, et al. Circulating follicular helper T cells in Crohn's disease (CD) and CD-associated colorectal cancer. *Tumour Biol*. 2014; 35:9355–9359. [PubMed: 24943684]
155. Shi W, et al. Dysregulation of circulating follicular helper T cells in nonsmall cell lung cancer. *DNA Cell Biol*. 2014; 33:355–360. [PubMed: 24593033]
156. Zhang M, et al. Thymic TFH cells involved in the pathogenesis of myasthenia gravis with thymoma. *Exp. Neurol*. 2014; 254:200–205. [PubMed: 24518487]
157. Bindea G, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. *Immunity*. 2013; 39:782–795. [PubMed: 24138885]
158. Petrovas C, et al. CD4 T follicular helper cell dynamics during SIV infection. *J. Clin. Invest*. 2012; 122:3281–3294. [PubMed: 22922258]
159. Hong JJ, Amancha PK, Rogers K, Ansari AA, Villinger F. Spatial alterations between CD4(+) T follicular helper, B, CD8(+) T cells during simian immunodeficiency virus infection: T/B cell homeostasis, activation, and potential mechanism for viral escape. *J. Immunol*. 2012; 188:3247–3256. [PubMed: 22387550]
160. Perreau M, et al. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. *J. Exp. Med*. 2013; 210:143–156. [PubMed: 23254284]
161. Lindqvist M, et al. Expansion of HIV-specific T follicular helper cells in chronic HIV infection. *J. Clin. Invest*. 2012; 122:3271–3280. [PubMed: 22922259]
162. Cubas RA, et al. Inadequate T follicular cell help impairs B cell immunity during HIV infection. *Nat. Med*. 2013; 19:494–499. [PubMed: 23475201]
163. Keele BF, et al. Characterization of the follicular dendritic cell reservoir of human immunodeficiency virus type 1. *J. Virol*. 2008; 82:5548–5561. [PubMed: 18385252]
164. Tenner-Racz K, von Stemm AM, Guhlk B, Schmitz J, Racz P. Are follicular dendritic cells, macrophages and interdigitating cells of the lymphoid tissue productively infected by HIV? *Res. Virol*. 1994; 145:177–182. [PubMed: 7800943]
165. Haase AT. Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. *Annu. Rev. Immunol*. 1999; 17:625–656. [PubMed: 10358770]
166. Gratten S, Cheynier R, Dumaurier MJ, Oksenhendler E, Wain-Hobson S. Highly restricted spread of HIV-1 and multiply infected cells within splenic germinal centers. *Proc. Natl. Acad. Sci. USA*. 2000; 97:14566–14571. [PubMed: 11121058]
167. Ringler DJ, et al. Cellular localization of simian immunodeficiency virus in lymphoid tissues. I. Immunohistochemistry and electron microscopy. *Am. J. Pathol*. 1989; 134:373–383. [PubMed: 2537016]
168. Harker JA, Lewis GM, Mack L, Zuniga EI. Late interleukin-6 escalates T follicular helper cell responses and controls a chronic viral infection. *Science*. 2011; 334:825–829. [PubMed: 21960530]

169. Vinuesa CG. HIV and T follicular helper cells: a dangerous relationship. *J. Clin. Invest.* 2012; 122:3059–3062. [PubMed: 22922252]
170. Moir S, Fauci AS. B cells in HIV infection and disease. *Nat. Rev. Immunol.* 2009; 9:235–245. [PubMed: 19319142]
171. Linterman MA, et al. Follicular helper T cells are required for systemic autoimmunity. *J. Exp. Med.* 2009; 206:561–576. [PubMed: 19221396]
172. West AP Jr, et al. Structural insights on the role of antibodies in HIV-1 vaccine and therapy. *Cell.* 2014; 156:633–648. [PubMed: 24529371]
173. Ahlers JD. All eyes on the next generation of HIV vaccines: strategies for inducing a broadly neutralizing antibody response. *Discov. Med.* 2014; 17:187–199. [PubMed: 24759623]
174. Haynes BF, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. *N. Engl. J. Med.* 2012; 366:1275–1286. [PubMed: 22475592]
175. Locci M, et al. Human circulating PD-(+)CXCR3(-)CXCR5(+) memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. *Immunity.* 2013; 39:758–769. [PubMed: 24035365]
176. Victora GD, et al. Germinal center dynamics revealed by multiphoton microscopy with a photoactivatable fluorescent reporter. *Cell.* 2010; 143:592–605. [PubMed: 21074050]



**Figure 1.**

Potential mechanism in the generation of human T<sub>FH</sub> subsets. As with other T<sub>H</sub> subsets, signals derived from antigen-presenting cells (including DCs) and the microenvironment instruct naive CD4<sup>+</sup> T cells to differentiate into the T<sub>FH</sub> lineage. The major cytokines driving the early T<sub>FH</sub> differentiation process in humans are IL-12 and IL-23, and TGF-β synergizes with these cytokines. Other STAT3-activating cytokines, including IL-6, IL-21 and IL-1β, also support this process in the presence of IL-12, IL-23 and TGF-β. The differentiation of human naive CD4<sup>+</sup> T cells is regulated by the balance of signals derived from these cytokines, and activated CD4<sup>+</sup> T cells differentiate into precursors of variable T<sub>H</sub> subsets such as T<sub>H</sub>1, T<sub>H</sub>17 and T<sub>FH</sub> cells. Some T<sub>FH</sub> precursors share properties of T<sub>H</sub>1 and T<sub>H</sub>17 cells (dotted rectangle in middle panel); interactions with B cells promote their differentiation into mature T<sub>FH</sub> cells, including T<sub>FH</sub>1 and T<sub>FH</sub>17 cells. The mechanism associated with the generation of T<sub>FH</sub>2 cells is currently unknown.

**Figure 2.**

Alteration of blood memory  $T_{FH}$  subsets in human autoimmune diseases. **(a)** Three parameters—CXCR3 versus CCR6, PD-1 and CCR7, and ICOS—can subdivide human blood memory  $T_{FH}$  cells ( $CD4^+CD45RA^-CXCR5^+$ ) into at least three  $T_{FH1}$ ,  $T_{FH2}$  and  $T_{FH17}$  subsets (nine  $T_{FH}$  subsets in total). PD-1 and CCR7 define two quiescent subpopulations,  $PD-1^-CCR7^{hi}$  and  $PD-1^+CCR7^{int}$ , and ICOS defines the  $ICOS^+PD-1^{2+}$  activated population within the blood memory  $T_{FH1}$ ,  $T_{FH2}$  and  $T_{FH17}$  subsets. The nine blood memory  $T_{FH}$  subsets are indicated in a three-dimensional scale. **(b)**  $T_{FH2}$  and  $T_{FH17}$  subsets represent efficient helpers among blood memory  $T_{FH}$  subsets. In the blood of patients with active autoimmune disease (such as SLE, juvenile dermatomyositis, Sjögren's syndrome or multiple sclerosis), the frequency of active ( $ICOS^+PD-1^{2+}$ )  $T_{FH2}$  and  $T_{FH17}$




subsets increases, whereas the frequency of T<sub>FH1</sub> subsets decreases. This alteration likely reflects the increase of functional T<sub>FH</sub> cells in lymphoid organs and/or inflamed tissues.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript



**Figure 3.**

Risk loci of human autoimmune diseases associated with the T<sub>FH</sub> developmental pathway. Multiple risk loci identified in GWAS in autoimmune diseases (indicated in red) are potentially associated with the regulation of the development and/or the function of human T<sub>FH</sub> cells. At least seven risk loci—*IL12A*, *IL12B*, *IL23R*, *STAT3*, *STAT4*, *IRF5* and *IRF8*—are associated with IL-12 and IL-23. *IRF8* also might contribute to TGF-β signaling by promoting the expression of TGF-β-activating integrin α<sub>v</sub>β<sub>8</sub> on the surface of DCs. Risk loci contain genes encoding T<sub>FH</sub>-specific molecules (such as *IL21* and *CXCR5*), as well as genes associated with the inhibition of T<sub>FH</sub> cell development (such as *PRDM1* and *PTPN22*). Whether and how these gene variants are associated with aberrant T<sub>FH</sub> responses in autoimmune diseases remains to be established.